 Standard care for stage-itesticular germ cell cancers, semenometous STC or non-semenometous NSTC, is orcheectomy followed by active surveillance, one or two cycles of adjuvant chemotherapy, surgery or radiotherapy. The decision on the adjuvant therapeutic approach is guided by the associated risk factors of the patient and the potential related toxicity of the treatment. Currently, there is no consensus regarding the optimal number of adjuvant chemotherapy cycles. Although in terms of overall survival, there is no proven inconsistency regarding the number of cycles of adjuvant chemotherapy and the rate of relapse may vary. This article was authored by Emanuella Florentina Rojos Nianu, Cyprian Deak and Kaleen Yoen Knapp.